Summit Therapeutics (SMMT) Q4 2025 earnings summary

Executive summary

• Ivonescimab, a PD-1/VEGF bispecific antibody, leads an advanced clinical pipeline with multiple global Phase III trials in NSCLC, CRC, and other solid tumors, supported by collaborations with Akeso, Revolution Medicines, GSK, and GORTEC.

• FDA accepted the BLA for ivonescimab in EGFR-mutated NSCLC, with a PDUFA target date of November 14, 2026, and commercial launch preparations underway.

• Over 4,000 patients have been treated in clinical trials and more than 60,000 commercially in China.

• New Phase III studies, including ILLUMINE in head and neck cancer, are set to launch in early Q2 2026, with expanded collaborations and patient dosing milestones.

• Positive Phase III results in NSCLC, including superiority over Keytruda in HARMONi-2 and over PD-1 plus chemo in HARMONi-6, highlight clinical momentum.

Financial highlights

• Ended 2025 with a cash and short-term investments balance of $713.4 million and no debt.

• Q4 2025 GAAP operating expenses were $225 million, down from $234.2 million in Q3; non-GAAP operating expenses rose to $113.3 million from $103.4 million.

• GAAP net loss for Q4 2025 was $219.2 million, improved from $231.8 million in Q3; non-GAAP net loss was $107.5 million, compared to $101.0 million in Q3.

• Full-year 2025 G&A spend (excluding stock-based compensation) was about $43 million, with a quarterly run rate of $10–11 million.

• GAAP operating expenses for 2025 surged to $1,094.4 million, mainly due to $681.4 million in stock-based compensation from performance-based stock option modifications.

Outlook and guidance

• Interim PFS analysis for HARMONi-3 squamous cohort expected in Q2 2026; final PFS and interim OS data in H2 2026.

• Non-squamous cohort enrollment to complete in H2 2026, with final PFS data anticipated in H1 2027.

• Additional global Phase III studies and novel combinations are planned for 2026, including ILLUMINE and new collaborations with GSK and Revolution Medicines.